Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAQ/5063 active extension and open-label laquinimod study in relapsing-remitting multiple sclerosis
2005-004334-41Phase 2Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of laquinimod in relapsing-remitting multiple sclerosis (RRMS) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Long-term safety. Started Oct 2005; status: terminated.
02
Drugs
laquinimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2005-004334-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004334-41.